Progranulin (PGRN) is a secreted glycoprotein with multiple biological functions, including modulation of wound healing and inflammation. Hypothalamic PGRN has been implicated in the development of sexual dimorphism. In the present study, a potential role for PGRN in the hypothalamic regulation of appetite and body weight was investigated. In adult rodents, PGRN was highly expressed in periventricular tanycytes and in hypothalamic neurons, which are known to contain glucose-sensing machinery. Hypothalamic PGRN expression levels were decreased under low-energy conditions (starvation and 2-deoxy-D-glucose administration) but increased under high-energy condition (postprandially). Intracerebrovetricular administration of PGRN significantly suppressed nocturnal feeding as well as hyperphagia induced by 2-deoxyglucose, neuropeptide Y, and Agouti-related peptide. Moreover, the inhibition of hypothalamic PGRN expression or action increased food intake and promoted weight gain, suggesting that endogenous PGRN functions as an appetite suppressor in the hypothalamus. Investigation of the mechanism of action revealed that PGRN diminished orexigenic neuropeptide Y and Agouti-related peptide production but stimulated anorexigenic proopiomelanocortin production, at least in part through the regulation of hypothalamic AMP-activated protein kinase. Notably, PGRN was also expressed in hypothalamic microglia. In diet-induced obese mice, microglial PGRN expression was increased, and the anorectic response to PGRN was blunted. These findings highlight a physiological role for PGRN in hypothalamic glucose-sensing and appetite regulation. Alterations in hypothalamic PGRN production or action may be linked to appetite dysregulation in obesity. (Endocrinology 152: 4672-4682, 2011) T he hypothalamus plays a central role in the regulation of feeding behavior and glucose metabolism during alterations in body energy state. These hypothalamic actions may depend on the ability to sense glucose levels (1). This idea is supported by the fact that local glucopenia in the hypothalamus induced by intrahypothalamic injection of the glucose antimetabolite 2-deoxy-D-glucose (2-DG) provokes neurohormonal and metabolic responses to hypoglycemia (2). In contrast, administration of glucose into the hypothalamus during systemic hypoglycemia prevents a physiological hypoglycemic response (3). Moreover, as with the pancreatic ␤-cells, some populations of hypothalamic neurons possess glucose-sensing machinery, such as glucose transporter 2 (GLUT2), glucokinase, sulfonylurea receptor 1, and ATP-sensitive K ϩ channels (4, 5). In addition to neurons, hypothalamic astroglial cells also express GLUT2, a subtype of glucose transporter involved in glucose sensing rather than in glucose uptake (6). Notably, the expression of GLUT2 in astroglial cells corrected defective glucose sensing in GLUT2-deficient
T he hypothalamus plays a central role in the regulation of feeding behavior and glucose metabolism during alterations in body energy state. These hypothalamic actions may depend on the ability to sense glucose levels (1) . This idea is supported by the fact that local glucopenia in the hypothalamus induced by intrahypothalamic injection of the glucose antimetabolite 2-deoxy-D-glucose (2-DG) provokes neurohormonal and metabolic responses to hypoglycemia (2) . In contrast, administration of glucose into the hypothalamus during systemic hypoglycemia prevents a physiological hypoglycemic response (3) . Moreover, as with the pancreatic ␤-cells, some populations of hypothalamic neurons possess glucose-sensing machinery, such as glucose transporter 2 (GLUT2), glucokinase, sulfonylurea receptor 1, and ATP-sensitive K ϩ channels (4, 5) . In addition to neurons, hypothalamic astroglial cells also express GLUT2, a subtype of glucose transporter involved in glucose sensing rather than in glucose uptake (6) . Notably, the expression of GLUT2 in astroglial cells corrected defective glucose sensing in GLUT2-deficient mice (7) , highlighting the importance of glucose sensing by nonneuronal cells.
Tanycytes are specialized glial cells lining the dorsolateral, ventrolateral, and floor regions of the third ventricle (3V) (8) . Because tanycytes differentiate from a subpopulation of radial glial cells during the perinatal period (9), they share some properties with astrocytes and radial glial cells. However, tanycytes also display unique and distinctive morphological, molecular, and functional characteristics. Four subtypes of tanycytes are currently known, termed ␣1-, ␣2-, ␤1-, and ␤2-tanycytes, and these differ in their anatomical localization and function (10, 11) . ␣1-and ␣2-tanycytes project single, long basal processes to the neurons and blood capillaries of the hypothalamic ventromedial and arcuate nuclei (ARC), respectively. In contrast, ␤-tanycytes are in contact with the portal capillaries of the median eminence, thereby serving as an anatomical link between the ventricular cerebrospinal fluid and the hypothalamo-hypophyseal portal circulation (12) . Interestingly, hypothalamic tanycytes express the glucose-sensing molecule GLUT2 and contain ATP-sensitive K ϩ channels (6) .
Moreover, the destruction of tanycytes by intracerebroventricular (icv) administration of the glucokinase inhibitor alloxan inhibited feeding and the hyperglycemic response to glucoprivation. In this study, impaired glucose counterregulatory responses returned to normal with the restoration of tanycyte destruction (13) . Thus, we speculated that tanycytes may sense glucose concentrations in the cerebrospinal fluid and thereby transmit information about energy status to hypothalamic neurons or to the portal system. Progranulin (PGRN), also known as proepithelin, acrogranin, prostate cancer cell-derived growth factor, or granulin-epithelin precursor, is an extracellular glycoprotein containing 7.5 copies of the cysteine-rich granulin motif (14, 15) . PGRN is ubiquitously expressed throughout the body but is particularly abundantly produced by epithelial and hematopoietic cells, in which PGRN expression levels are closely related to the extent of cellular mitotic activity (16) . PGRN is known as a growth factor that regulates cell division, survival, and migration (17) . Substantial evidence supports the idea that PGRN is a pivotal player in wound repair, inflammatory responses, and cancer growth and metastasis (15, 18, 19) . In the central nervous system, PGRN is expressed in neurons and microglia (20) . Mutations in the gene encoding PGRN in humans are associated with neuronal atrophy of the frontal and temporal lobes, leading to a familial dementia known as frontotemporal lobar degeneration (20, 21) . PGRN expression in hypothalamic neurons is up-regulated by estrogen during embryogenesis and in the early postnatal period (22) . Furthermore, PGRN-deficient mice display diminished male sexual behavior, suggesting that PGRN plays an essential role in establishing male sexual behavior (23) .
Our preliminary study showed that PGRN was highly expressed in the hypothalami of adult rodents. We therefore investigated the involvement of PGRN in hypothalamic regulation of appetite and body weight. 
Materials and Methods

Materials
Animals
Eight-to 10-wk-old male C57BL6 mice and Sprague Dawley rats were purchased from Japan SLC, Inc. (Hamamatsu, Japan). Animals were allowed free access to a standard chow diet (Agripurina, Inc., Seoul, Korea) and water, unless otherwise indicated. Animals were housed under temperature-controlled conditions (21 Ϯ 1 C) on a 12-h light, 12-h dark cycle, with lights on from 0700 to 1900 h. To generate diet-induced obesity (DIO), mice were fed a high-fat and high-sucrose diet (D12331; Research Diets, Inc., New Brunswick, NJ) for 10 wk. Lean control mice were fed a chow diet for the same period. All procedures were performed in accordance with the Principles of Laboratory Animal Care (National Institutes of Health, Washington, D.C.) and were approved by the Institutional Animal Care and Use Committee of the Asan Institute for Life Sciences.
Cannulation and injection
Permanent 26-gauge stainless steel cannulae were implanted into the 3rd ventricle [intra-3V (i3V)] (1.8 mm caudal to bregma and 5.0 mm ventral to the sagittal sinus) or bilaterally into the mediobasal hypothalamus (MBH) [intra-MBH (iMBH)] (1.8 mm caudal to bregma, 0.25 mm lateral, and 5.5 mm ventral to the sagittal sinus) of mice, as described previously (24) . After a 1-wk recovery period, mice were handled daily for 3 d to acclimatize them to the injection procedure. Correct positioning of i3V-implanted cannulae was established by verifying the presence of a dipsogenic response to angiotensin II (50 ng). The correct positioning of each iMBH cannula was confirmed by histological examination performed by an independent observer after each animal was killed. Only mice with correctly positioned cannulae were included in the analysis. The peptides, 2-DG, and AICAR were dissolved in 0.9% (wt/vol) saline and administered in a total volume of 2.5 l for i3V injection and 1 l for iMBH injection. Most experiments were performed in the early light phase (0900 -1100 h) on overnight-fasted mice unless indicated. Feeding studies using 2-DG and PGRN antibody were conducted in the early light phase (0900 -1100 h) with freely fed mice. Studies using NPY and AGRP and the nocturnal PGRN feeding study were performed just before lights-off (1800 -1900 h) in mice with free access to food. Food intake and body weight were monitored for 24 h after injection.
Small interfering RNA (siRNA)
siRNA specific to murine PGRN was purchased from Dharmacon (Chicago, IL). For animal studies, siRNA particles were resuspended in ribonuclease-free water and mixed with lipofectamine (9:1 vol/vol; Invitrogen, Carlsbad, CA) to achieve a final concentration of 1 mM just before use. PGRN siRNA (0.5 l each side) was injected bilaterally into the MBH over a 5-min period during stereotaxic surgery as previously described (24) . The same volume of nontargeting scrambled control siRNA (Dharmacon) was administered to the control group. The MBH was harvested on the third day after siRNA injection after a 5-h fast. Hypothalamic PGRN protein levels were determined by an immunoblotting assay. When hypothalamic PGRN levels were less than 40% of the average of the control group, gene knockdown was considered successful (see figure 3 below). Animals showing successful gene knockdown were included in the analysis.
Conditioned taste aversion (CTA) test
We conducted CTA tests using a previously described protocol (25) . Mice were habituated to 1 h daily access to water. During this hour, two bottles, each containing unflavored tap water, were placed in the home cage. After 7 d, all mice received two bottles containing 0.15% saccharin solution instead of water. Immediately after this 1-h saccharine exposure, mice received either sequential injection of ip saline and i3V saline, ip lithium chloride (LiCl) (127 mg/kg; Sigma, St. Louis, MO) and i3V saline or ip saline and i3V PGRN (1 g). For the next 3 d, a two-bottle choice test was conducted, in which mice were allowed 1-h access to one bottle containing tap water and another bottle containing the saccharin solution. Preference ratio was calculated as the intake of saccharine solution/total intake of water and saccharine solution.
Immunofluorescence (IF) staining
Rats were killed by decapitation after a 5-h fast. Whole brains were collected and quickly frozen in isopentane prechilled with liquid nitrogen. Brain slices (15-m thickness), including the hypothalamus, were fixed with 4% paraformaldehyde for 30 min at room temperature and permeabilized with 0.2% (vol/vol) Triton X-100. After blocking with 3% (vol/vol) goat serum (Sigma) for 1 h, slides were incubated with a primary antibody against PGRN (1:1000, sheep; R&D Systems, Minneapolis, MN), the specificity of which was tested using PGRN knockout mice (26) at 4 C overnight. After washing, slides were incubated with Alexa Fluor 555-conjugated donkey antisheep antibody (Invitrogen) at room temperature for 1 h. Stained tissues were examined and photographed using confocal laser scanning microscopy (Leica, Wetzlar, Germany). For double IF staining of PGRN and the tanycyte marker vimentin (9) 
Immunoblotting
Animals were killed by decapitation in different feeding states or 1 h after administration of 2-DG. The medial hypothalamus was dissected, and immunoblotting was performed as previously described (27) using antibodies against PGRN (1:2000, rabbit; AdipoGen), and total and phosphorylated (Thr172)-AMP-activated protein kinase (AMPK) (1:1000, rabbit; Cell Signaling, Beverly, MA).
Measurement of AMPK activity
AMPK was partially purified from medial hypothalamus tissue lysate or from SH-SY5Y cell lysate by the addition of saturated ammonium sulfate to a final concentration of 35% (vol/ vol), followed by incubation on ice for 15 min. The AMPK activity of protein fractions was determined in kinase assay buffer [62.5 mM HEPES (pH 7.0), 62.5 mM NaCl, 62.5 mM NaF, 6.25 mM sodium pyrophosphate, 1.25 mM EDTA, 1. Reactions were terminated by the spotting of the reaction mixture onto phosphocellulose paper (P81), which was subsequently washed with 150 mM phosphoric acid. Radioactivity was measured using a scintillation counter. For the measurement of isoform-specific AMPK activity, hypothalamic protein lysate (40 g) was immunoprecipitated by incubation with specific antibodies against the ␣1-and ␣2-AMPK catalytic subunits (2 g; Cell Signaling) and 20 l of 25% (wt/vol) protein GSepharose beads (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) overnight at 4 C.
Real-time PCR
The medial hypothalamus was dissected out as described in the immunoblotting section and stored at Ϫ70 C until assayed. Total RNA was extracted using TRIzol reagent (Invitrogen). Hypothalamic mRNA content for PGRN, NPY, AGRP, POMC, ␣2-, ␤1-, and ␤2-AMPK was determined using real-time PCR analysis (PerkinElmer, Waltham, MA) using primers listed in Supplemental Table 1 , published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org. The expression level of each mRNA was normalized to that of glyceraldehyde 3-phosphate dehydrogenase mRNA.
Promoter activity
GT1-7 hypothalamic neuronal cells were maintained in DMEM with 10% fetal bovine serum, plated on 12-well plates, and transfected with a luciferase reporter construct containing human NPY promoter (Ϫ963 to ϩ67 nucleotides; pNPY-luc; 50 ng), human AGRP promoter (Ϫ1000 to Ϫ1 nucleotides; pAGRP-luc; 25 ng), or human POMC promoter (Ϫ877 to ϩ320 nucleotides; pPOMC-luc, 200 ng) and the CMV-␤-gal (50 ng) gene using Lipofectamine (Invitrogen), as previously described (24) . Forty-eight hours after transfection, cells were treated with PGRN (10 nM) with or without AICAR (5 M) for 4 h. Luciferase activity was normalized to that of ␤-galactosidase, and data are reported as fold changes compared with controls. Transfections were performed in duplicate and all experiments were repeated at least three times.
Data analysis
All data are presented as means Ϯ SEM. Comparisons between two groups were performed using Student's t test. For comparisons among three or more groups, repeated or one-way ANOVA was performed and followed by the application of a post hoc least significant differences test. The significance level was defined as P Ͻ 0.05.
Results
Distribution of PGRN in the hypothalamus
PGRN immunoreactivity was observed in the long basal processes of hypothalamic tanycytes in adult rats, which had strong immunoreactivity against the tanycyte marker vimentin (Fig. 1, A and B) . PGRN was also highly expressed in the cytoplasm and axonal processes of hypothalamic neurons. Such neurons were further characterized by double immunostaining of PGRN with NPY or with the POMC product ␤-endorphin. PGRN immunoreactivity was found in most NPY-and POMC-producing neurons (Fig. 1C) .
Effects of PGRN on food intake and body weight
Abundant expression of PGRN in the hypothalamus led us to speculate that PGRN might play a role in the central regulation of energy balance. To test this hypothesis, we injected several doses of human PGRN peptide (0.3-3 g) into the 3V (i3V) adjacent to the hypothalamus in overnight-fasted mice. The i3V injection of PGRN (1 or 3 g) resulted in a significant and dose-dependent reduction in fasting-induced feeding (Fig. 2A) . These effects remained significant for 24 h after injection. Moreover, mice injected with PGRN gained less weight over the 24 h after injection period (Fig. 2B) . To test the effects of PGRN under more physiological conditions, we injected PGRN (1 g) i3v just before lights-off in freely fed mice. i3V PGRN administration significantly suppressed nocturnal feeding and body weight gain (Fig. 2, C and D) . We also injected PGRN (0.1-1 g) directly into the MBH (iMBH) of overnight-fasted mice. iMBH injection of PGRN also repressed both food intake and body weight gain even at a 10-fold lower dose (0.1 g) than the effective dose for icv injection (Fig. 1, E and F) . These findings suggest that PGRN controls food intake via a mechanism involving the MBH.
To exclude the possibility that PGRN suppresses food intake by causing nausea and malaise, we conducted a CTA test after administration of PGRN. As a positive control, we administered LiCl ip. Intraperitoneal injection of LiCl reduced saccharin consumption by approximately 35% (Fig. 2G) , confirming the successful induction of CTA. In contrast, i3V administration of PGRN did not reduce saccharin consumption compared with vehicle injection (Fig. 2G) . These results indicate that the anorexic effect of PGRN was not due to systemic toxicity or illness.
Effects of blockade of hypothalamic PGRN on food intake and body weight
To examine whether endogenous hypothalamic PGRN controls food intake and body weight, we sought to inhibit hypothalamic PGRN production by bilaterally injecting siRNA specific to murine PGRN into the MBH. iMBH administration of PGRN siRNA significantly decreased hypothalamic PGRN protein expression by approximately 70% (Fig. 3A) . Injection of PGRN siRNA increased food intake and accelerated recovery from weight loss in the postoperative period compared with 
the injection of control siRNA (Fig. 3, B and C) . Similarly, i3V injection of a neutralizing antibody against PGRN (3 g, rabbit; AdipoGen) stimulated food intake and weight gain compared with the injection of the same dose of antirabbit IgG (Amersham, Piscataway, NJ) (Fig. 3, D and E). Together, these findings indicate that PGRN produced locally in the hypothalamus exerts anorexigenic and weight-loss effects.
Changes in hypothalamic PGRN levels by body energy state
If endogenous PGRN plays a role in the hypothalamic control of energy metabolism, we hypothesized that alterations in nutritional status or glucose availability might affect hypothalamic PGRN expression. We therefore determined the changes in hypothalamic PGRN expression in mice that had been fasted and refed. Hypothalamic PGRN protein and mRNA levels were diminished during a 24-h fast but rose when food was reintroduced (Fig. 4, A and B) . We also examined the effects of glucopenia on hypothalamic PGRN expression. Glucopenia was induced by i3V administration of 2-DG (15 nmol) in freely fed mice in the early light phase. As seen under fasting conditions, i3V injection of 2-DG in satiated mice potently suppressed both the protein and mRNA expression of PGRN in the hypothalamus   FIG. 3 . Inhibition of hypothalamic PGRN expression or action stimulates food intake and weight gain. A, Intrahypothalamic administration of siRNA specific to murine PGRN significantly suppressed hypothalamic PGRN expression (n ϭ 4 -5). B and C, Hypothalamic PGRN knockdown increased basal food intake and accelerated weight gain during the postoperative period (n ϭ 4 -5). D and E, Effects of i3V administration of PGRN antibody on food intake and body weight in satiated mice (n ϭ 6). *, P Ͻ 0.05 vs. controls.
FIG. 2.
Central administration of PGRN decreases food intake and body weight. A and B, i3V administration of PGRN to overnight-fasted mice significantly suppressed fasting-induced feeding and body weight gain in a dose-dependent manner (n ϭ 6 -7). C and D, i3V PGRN reduced nocturnal feeding and weight gain (n ϭ 6). E and F, Effects of iMBH administration of PGRN on food intake and body weight in fasted mice (n ϭ 5-6). G, CTA test after i3V PGRN or ip LiCl (n ϭ 5). *, P Ͻ 0.05; **, P Ͻ 0.01 vs. saline-administered controls. NS, Not significant. (Fig. 4, C and D) , providing evidence that PGRN expression levels in this tissue are indeed down-regulated when fuel levels are low. Consistent with this idea, immunohistochemical analysis revealed that PGRN immunoreactivity was decreased in both tanycytes and hypothalamic neurons in 2-DG-injected mice (Fig. 4E) .
Both central and peripheral administration of 2-DG cause hyperphagia in rodents (29, 30) , which may help animals recover from intracellular energy shortages. Because hypothalamic PGRN expression was negatively regulated by 2-DG, we next investigated the role of hypothalamic PGRN in 2-DG-induced hyperphagia. PGRN (1 g) was injected i3V 30 min before ip injection of 2-DG (0.5 mg/kg) in mice with ad libitum access to food during the early light period. Consistent with previous reports (29, 30) , administration of 2-DG to satiated mice significantly increased food intake at 2 and 8 h after injection (Fig. 4, F and G) . Previous i3V administration of PGRN completely blocked 2-DG-stimulated food intake, suggesting that a 2-DG-induced reduction in hypothalamic PGRN levels is critical for hyperphagic responses to 2-DG. Our findings collectively support a physiological role of PGRN in hypothalamic glucose sensing and subsequent adaptive behavioral responses.
PGRN suppresses hypothalamic AMPK
AMPK, an enzyme activated in response to low cellular energy levels, is a key player in recovery from energy depletion (31) . Hypothalamic AMPK activity is altered by changes in body energy state or by administration of appetite-regulating hormones and chemicals (32) (33) (34) . Moreover, hypothalamic AMPK functions as a downstream mediator of various appetite regulators, including 2-DG (32). We therefore tested whether AMPK might act as a downstream effector of hypothalamic PGRN action. We found that the i3V administration of PGRN (1 g) into overnight-fasted mice suppressed total hypothalamic AMPK activity by approximately 20% at 2 h after injection (Fig. 5A) . When we determined isoform-specific AMPK activity, i3V PGRN-injected animals showed suppressed hypothalamic ␣2-AMPK activity but not ␣1-AMPK activity at 2 h after injection (Fig. 5B) . Phosphorylated AMPK levels, an indicator of AMPK activation, were consistently decreased by PGRN administration (Fig. 5C) . We further investigated the mechanism of PGRN-induced suppression of hypothalamic AMPK and found that i3V PGRN decreased total AMPK protein levels and ␣2-AMPK mRNA levels (Fig. 5, C and D) , suggesting that PGRN inhibits AMPK production. In line with these in vivo data, treatment with PGRN (1 nM) decreased AMPK activity in SH-SY5Y neuronal cells (Fig. 5E ), and this effect was reversed by cotreatment with the AMPK activator AICAR (5 M).
To determine whether the PGRN-induced reduction in AMPK activity is important for the anorexigenic effects of PGRN, we injected AICAR (30 pmol) through i3V-implanted cannulae 30 min before administration of PGRN (1 g) in overnight-fasted mice. This small dose of AICAR did not significantly alter food intake and body weight at 24 h after injection (Fig. 5, F-H) . Nevertheless, treatment with AICAR at this subeffective dose was able to block PGRN-induced anorexia and weight loss. These data support a role for hypothalamic AMPK as a downstream signaling molecule for PGRN.
Relationships between PGRN and appetiteregulating neuropeptides
To further identify the molecular mechanisms by which PGRN induces anorexia and weight loss, we examined changes in hypothalamic appetite-regulating neuropeptides after administration of PGRN. i3V administration of PGRN (1 g) to overnight-fasted mice significantly decreased both hypothalamic NPY and AGRP mRNA levels but increased POMC mRNA levels 2 h after injection (Fig.  6A) . We therefore tested the effects of PGRN on the transcriptional activity of NPY, AGRP, and POMC in vitro. Treatment of GT1-7 hypothalamic neuronal cells with PGRN peptide significantly suppressed the promoter activity of NPY and AGRP (Fig. 6, B and C) . Moreover, cotreatment with AICAR (5 M) completely blocked the inhibitory effects of PGRN on NPY and AGRP promoter activity. In contrast, PGRN treatment in GT1-7 cells stimulated POMC transcriptional activity, which was also reversed by cotreatment with AICAR (Fig. 6D) . These findings indicate that PGRN regulates the transcription of NPY, AGRP, and POMC via the suppression of AMPK.
We next examined whether the administration of NPY and AGRP could reverse the effects of PGRN on feeding. For this study, NPY (3 g) or AGRP (4 g) was administered 30 min before PGRN just before the beginning of the dark cycle in freely fed mice. i3V injection of NPY and AGRP further stimulated nighttime food intake, confirming the orexigenic effects of these peptides (Fig. 6, E and F) . The PGRN-induced reduction in nocturnal feeding was inhibited by the previous administration of NPY and AGRP (Fig. 6, E and F ), indicating that PGRN modulates feeding behavior through hypothalamic NPY and the melanocortin system. 
Changes in PGRN expression and action in DIO mice
Obese humans have increased levels of serum PGRN, and circulating PGRN levels are reported to reflect macrophage infiltration of adipose tissue (35) . Consumption of a high-fat diet has been associated with increased hypothalamic inflammation and gliosis (36) . Because PGRN is known as an important regulator of inflammatory responses, we investigated the expression of PGRN in hypothalamic microglia, which reside largely in the median eminence and to a lesser extent in the MBH (Fig. 7B) . PGRN was coexpressed with Iba1, a marker of microglia (37) , in the hypothalamic ARC and median eminence of chow diet-fed lean mice (Fig. 7, A and B) . Both Iba1 and PGRN immunoreactivity were significantly elevated in DIO mice (Fig. 7B) , suggesting that microglial PGRN increases in obese condition. Interestingly, PGRN immunoreactivity in hypothalamic ARC neurons and tanycytes showed a tendency of increase in DIO mice (Fig. 7A ). Finally, we tested the effects of PGRN on feeding in DIO mice. i3V administration of PGRN reduced fastinginduced feeding in lean mice, but this effect was attenuated in DIO mice (Fig. 7, C and D) . These data suggest that resistance to the anorexigenic effects of PGRN may contribute to hyperphagia in obesity.
Discussion
In the present study, we have shown that PGRN is abundantly expressed in hypothalamic tanycytes and neurons of adult rodents. Expression of hypothalamic PGRN is altered according to fuel availability. Moreover, administration of PGRN causes anorexia and inhibits body weight gain. Collectively, these findings indicate that hypothalamic PGRN functions as an active regulator of body energy homeostasis. Previous studies have shown that hypothalamic PGRN expression is regulated by sex hormones and plays an important role in the development of sexual behavior (38, 39) . Thus, PGRN has multiple biological functions in the hypothalamus.
The importance of hypothalamic PGRN in energy metabolism remains to be established. PGRN expression in glucose-sensing cells suggests a potential role for PGRN in hypothalamic glucose sensing and behavioral adaptation to glucose availability. Supporting this notion, hypotha- lamic PGRN expression was down-regulated by fasting and 2-DG injection. Moreover, hyperphagia induced by fasting and 2-DG administration was inhibited by central administration of PGRN, suggesting an involvement of PGRN in glucoprivic feeding. On the other hand, PGRN was expressed in hypothalamic NPY and POMC neurons, key players in appetite regulation and regulated the transcription of NPY, AGRP, and POMC. Administration of PGRN just before light-off suppressed nocturnal feeding, whereas inhibition of PGRN production or action in the hypothalamus increased basal food intake and body weight. These findings support a physiological role for PGRN in the control of normal fasting-feeding cycles. PGRN was abundantly expressed in the axons and cytoplasm of neurons in the MBH. Moreover, a much lower dose of PGRN reduced food intake when directly administered into the MBH. Thus, PGRN produced in the MBH may act on hypothalamic neurons in an autocrine or paracrine fashion to modulate feeding behavior. However, direct administration of PGRN into the MBH produced a faster but less dramatic delayed feeding effect compared with icv administration, suggesting that other hypothalamic areas or other brain regions may be involved in the late anorexigenic effects of PGRN. Because PGRN is ubiquitously expressed in neurons in multiple brain regions (26) , it is also possible that PGRN is secreted from the axon terminals of extrahypothalamic neurons projecting to the hypothalamus and modulates the function of hypothalamic neurons. On the other hand, PGRN is highly expressed in hypothalamic tanycytes. Thus PGRN released from the basal processes of tanycytes may act on the hypothalamic neurons in contact with those tanycytes. However, in the present study, we could not differentiate the regulation and function of tanycyte-derived PGRN from that of neuron-derived PGRN. If it were technically possible, it would be interesting to determine which pool of PGRN is more important for central metabolic regulation. The receptors mediating the central metabolic effects of PGRN have not yet been identified. A recent paper demonstrated that PGRN binds to sortilin with high affinity (40) . PGRN binding to sortilin leads to endocytosis and lysosomal degradation and has been proposed as a mechanism for the regulation of extracellular PGRN content. However, a role for sortilin in PGRN signal transduction is not evident so far.
Hypothalamic AMPK is a downstream signaling molecule common to many appetite regulators. Administration of the glucose antimetabolite 2-DG enhances hypothalamic AMPK activity (32) . Moreover, central administration of an AMPK inhibitor blocks 2-DG-induced hyperphagia, suggesting an important role for hypothalamic AMPK activation in glucoprivic feeding. In the present study, PGRN suppressed hypothalamic AMPK expression and, therefore, activity, whereas coadminis-
FIG. 7.
Increased microglial PGRN expression and reduced anorectic response to PGRN in DIO mice. A and B, PGRN expression in microglia stained with Iba1 in the hypothalamic ARC and median eminences (ME) of lean and DIO mice. C and D, The anorexigenic effect of i3V PGRN was blunted in DIO mice (n ϭ 5). *, P Ͻ 0.05 vs. saline-administered lean controls. NS, Not significant. tration of the AMPK activator AICAR reversed the anorexigenic effects of PGRN. Thus, a PGRN-induced decrease in hypothalamic AMPK activity may be critical for the regulation of feeding behavior by PGRN. In agreement with this, cotreatment with AICAR prevented PGRN-induced changes in NPY, AGRP, and POMC transcriptional activity. These findings indicate that PGRN regulates the appetite and expression of neuropeptides at least in part through the inhibition of hypothalamic AMPK. However, we cannot exclude the possibility of involvement of other signaling pathways in PGRN-mediated control of feeding behavior. Future investigation will be warranted to fully understand these mechanisms.
PGRN can have both pro-and antiinflammatory properties, because the antiinflammatory PGRN can undergo proteolysis to become the proinflammatory granulin (15) . Recently, it has been shown that circulating PGRN levels are closely correlated with adiposity and macrophage infiltration in visceral fat (35) . Moreover, PGRN treatment stimulates monocyte chemotaxis. In the brain, PGRN is strongly expressed in macrophages and microglia in active multiple sclerosis lesions (41) . In line with these findings, we have demonstrated PGRN expression in hypothalamic microglia. Moreover, obese mice displayed an elevation in microglial PGRN expression together with increased microglial infiltration in the hypothalamic ARC and median eminence, raising the possibility that increased microglial PGRN may be associated with hypothalamic gliosis and inflammation. However, it is currently unknown if microglial PGRN plays a role in hypothalamic regulation of food intake. Notably, obese mice had a reduced anorectic response to PGRN along with a tendency of increased PGRN expression in hypothalamic neurons and tanycytes. These findings suggest that DIO mice develop PGRN resistance in the hypothalamus through as yet unknown mechanisms. A similar central resistance to the wellknown anorexigenic hormone leptin is observed in obese animals (42) . Thus, reduced anorectic response to PGRN may account for appetite dysregulation in obesity, although future studies are needed to unveil the molecular mechanisms underlying this phenomenon.
In summary, hypothalamic PGRN expression levels drop in energy-depleted states, resulting in hyperphagia through AMPK-mediated transcriptional regulation of NPY, AGRP, and POMC. In contrast, obesity is associated with elevated PGRN expression in the hypothalamic microglia and a reduced response to PGRN. Our findings establish hypothalamic PGRN as a novel appetite-regulating peptide.
